Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H34O15 |
Molecular Weight | 610.5606 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(O)C=C(C=C1)[C@@H]2CC(=O)C3=C(O)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C=C3O2
InChI
InChIKey=QUQPHWDTPGMPEX-QJBIFVCTSA-N
InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1
Molecular Formula | C28H34O15 |
Molecular Weight | 610.5606 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Hesperidin
http://www.bimsifram.fr/hesperidin/indications_and_usage_of_hesperidin.htm
Curator's Comment: description was created based on several sources, including:
https://en.wikipedia.org/wiki/Hesperidin
http://www.bimsifram.fr/hesperidin/indications_and_usage_of_hesperidin.htm
Hesperidin is a flavanone glycoside found in citrus fruits. Its aglycone form is called hesperetin. Its name is derived from the word "hesperidium", for fruit produced by citrus trees. Hesperidin was first isolated in 1828 by French chemist Lebreton from the white inner layer of citrus peels (mesocarp, albedo). As a flavanone found in citrus fruits (such as oranges, lemons or pummelo fruits), hesperidin is under laboratory research for possible biological properties. One area of research is focused on the possible chemopreventive effects of hesperidin, but there is no current proof that hesperidin has this role in human cancer mechanisms. Hesperidin was effective in an animal model of Alzheimer's, alleviating pathological changes induced by aluminum. Early research suggests that taking one tablet of a specific product (Daflon 500, Les Laboratoires Servier) containing hesperidin and diosmin by mouth for 45 days decreases blood sugar levels and improves blood sugarcontrol in women with type 2 diabetes. For Rheumatoid arthritis (RA): early research suggests that drinking a beverage containing alpha-glucosyl hesperidin for 12 weeks improves symptoms of RA. Orally, hesperidin can cause gastrointestinal side effects, including abdominal pain, diarrhea, and gastritis. Headache can also occur in some patients. The possible anti-inflammatory action of hesperidin is probably due to the possible anti-inflammatory action of its aglycone hesperetin. Hesperetin appears to interfere with the metabolism of arachidonic acid as well as with histamine release. Hesperetin appears to inhibit phospholipase A2, lipoxygenase and cyclo-oxygenase. There is evidence that hesperetin inhibits histamine release from mast cells, which would account for the possible anti-allergic activity of hesperidin. The possible hypolipidemic effect of hesperidin is probably due to hesperetin's possible action in lipid lowering. Hesperetin may reduce plasma cholesterol levels by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, as well as acyl coenzyme A: cholesterol acytransferase (ACAT). Inhibition of these enzymes by hesperetin has been demonstrated in rats fed a high cholesterol diet. The mechanism of hesperidin's possible vasoprotective action is unclear. Animal studies have shown that hesperidin decreases microvascular permeability. Hesperidin, itself or via hesperetin, may protect endothelial cells from hypoxia by stimulating certain mitochondrial enzymes, such as succinate dehydrogenase. The mechanism of hesperidin's possible anticarcinogenic action is also unclear. One explanation may be the inhibition of polyamine synthesis. Inhibition of lipoxygenase and cyclo-oxygenase is another possibility.
CNS Activity
Curator's Comment: Hesperidin (HESP), a flavanone glycoside, shows high antioxidant properties and posses ability to go through the blood–brain barrier. Therefore, it could be a potential drug molecule against aggregation based diseases such as Alzheimer’s, Parkinson’s, and systemic amyloidoses.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | FRUIT ALLERGEN MIX Approved UseFor the temporary relief of symptoms related to allergies to Vitamin C in foods and supplements, including fatigue, upper respiratory, gastrointestinal, musculoskeletal, and urinary symptoms. |
|||
Inactive ingredient | Volu-Firm Eye Renewal Cream Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-AIDS agents, 10. Acacetin-7-O-beta-D-galactopyranoside, an anti-HIV principle from Chrysanthemum morifolium and a structure-activity correlation with some related flavonoids. | 1994 Jan |
|
Inhibition of HIV activation in latently infected cells by flavonoid compounds. | 1996 Jan 1 |
|
The immunomodulation of endotoxin-induced acute lung injury by hesperidin in vivo and in vitro. | 2007 Apr 24 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.akins.com/ns/DisplayMonograph.asp?storeID=a59a6b1c10e44c9e9420a7a75b27460a&DocID=hesperidin
Curator's Comment: There is not enough evidence concerning doses of hesperidin used alone. Most studies describe the use of hesperidin in combination products that also contain other ingredients.
For arthritis: beverages containing 3 grams of a hesperidin derivative have been used every morning for 12 weeks.
For blood vessel disorders (easily damaged capillary blood vessels): one tablet of Daflon ( 90% diosmin and 10% other flavonoids expressed as hesperidin.) has been used twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23656891
in vitro assay, a concentration of 200 μg/ml of hesperidin resulted in the mortality of 100% adult worms of Schistosoma (S.) mansoni within 72 h and a partial tegumental alteration in 10% of worms.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:08 GMT 2023
by
admin
on
Fri Dec 15 15:35:08 GMT 2023
|
Record UNII |
E750O06Y6O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
83 (Number of products:829)
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
||
|
NCI_THESAURUS |
C68461
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
520-26-3
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
28775
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
SUB14093MIG
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
C506722
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
HESPERIDIN
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
44184
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
DB04703
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
m5976
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
C68460
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
10621
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
D006569
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
5281
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
1304377
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
DTXSID9044328
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
100000088498
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
E750O06Y6O
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL449317
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
61606
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
208-288-1
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY | |||
|
E750O06Y6O
Created by
admin on Fri Dec 15 15:35:08 GMT 2023 , Edited by admin on Fri Dec 15 15:35:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
NMT 5%
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |